NOVOCURE LIMITED
NVCR JE00BYSS4X48
NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.
Annual Performance 1
| 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -53% | -8% | -78% | 107% | 0% |
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
| Person | Price | Shares | Total | Published | Completed |
|---|---|---|---|---|---|
| Cordova Ashley CEO |
12.22 USD |
81,550 Bought |
996,859 USD |
05/09/2025 | 05/09/2025 |
| Cordova Ashley CEO |
12.22 USD |
81,550 Bought |
996,859 USD |
05/09/2025 | 05/09/2025 |
| Cordova Ashley CEO |
12.22 USD |
81,550 Bought |
996,859 USD |
05/09/2025 | 05/09/2025 |
| Brackmann Christoph CFO |
11.60 USD |
5,000 Bought |
58,000 USD |
29/07/2025 | 29/07/2025 |
| Brackmann Christoph CFO |
11.63 USD |
10,000 Bought |
116,300 USD |
29/07/2025 | 29/07/2025 |
| Brackmann Christoph CFO |
11.50 USD |
5,000 Bought |
57,500 USD |
29/07/2025 | 29/07/2025 |
| Hilleman Jeryl L O |
17.26 USD |
999 Sold |
17,247 USD |
03/06/2025 | 03/06/2025 |
| Hilleman Jeryl L O |
17.26 USD |
999 Sold |
17,247 USD |
03/06/2025 | 03/06/2025 |
| Scannell Timothy J O |
17.32 USD |
999 Sold |
17,299 USD |
03/06/2025 | 03/06/2025 |
| Leung Gabriel O |
17.31 USD |
999 Sold |
17,297 USD |
03/06/2025 | 03/06/2025 |